Press release, Helsinki, 2 October 2024 at 9 AM (EEST)
Nexstim Receives NBS System 5 Order from European Customer
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer.
Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for non-invasive mapping of the primary motor cortex of the brain. The system provides information that may be used in pre-procedural planning. In addition to the diagnostic features, this specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depression and chronic neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “This customer is an experienced user of our system especially in the treatment of chronic pain, and we have been pleased to see them achieve great results using our system. Our combined system option enables also our existing customers to expand the use of their Nexstim systems, offering interesting possibilities for multi-departmental use of the device.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
